Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2016, Article ID 2867916, 9 pages
http://dx.doi.org/10.1155/2016/2867916
Research Article

Regional Variation across Canadian Centers in Radioiodine Administration for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer Diagnosed in 2000–2010

1Department of Nuclear Medicine, Western University, London, ON, Canada
2Department of Radiation Oncology, Dalhousie University, Halifax, NS, Canada
3Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada
4Department of Endocrinology, Women’s College Hospital, Toronto, ON, Canada
5Department of Radiology and Nuclear Medicine, Memorial University, St. John’s, NL, Canada
6Department of Medicine, Dalhousie University, Halifax, NS, Canada
7Department of Surgery, McMaster University, Hamilton, ON, Canada
8Department of Surgery, University of Manitoba, Winnipeg, MB, Canada
9Department of Medicine, Western University, London, ON, Canada

Received 28 July 2016; Accepted 20 October 2016

Academic Editor: Julie A. Sosa

Copyright © 2016 I. Rachinsky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Davies and H. G. Welch, “Increasing incidence of thyroid cancer in the United States, 1973–2002,” Journal of the American Medical Association, vol. 295, no. 18, pp. 2164–2167, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. L. F. Ellison and K. Wilkins, “Cancer prevalence in the Canadian population,” Health Reports, vol. 20, no. 1, pp. 7–19, 2009. View at Google Scholar · View at Scopus
  3. M. Schlumberger, B. Catargi, I. Borget et al., “Strategies of radioiodine ablation in patients with low-risk thyroid cancer,” The New England Journal of Medicine, vol. 366, no. 18, pp. 1663–1673, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. U. Mallick, C. Harmer, B. Yap et al., “Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer,” The New England Journal of Medicine, vol. 366, no. 18, pp. 1674–1685, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. D. S. Cooper, G. M. Doherty, B. R. Haugen et al., “Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 19, no. 11, pp. 1167–1214, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. R. Haymart, D. G. Muenz, A. K. Stewart, J. J. Griggs, and M. Banerjee, “Disease severity and radioactive iodine use for thyroid cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 2, pp. 678–686, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. A. M. Sawka, L. Rotstein, J. D. Brierley et al., “Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States,” Thyroid, vol. 17, no. 12, pp. 1235–1242, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Mao and M. Xing, “Recent incidences and differential trends of thyroid cancer in the USA,” Endocrine-Related Cancer, vol. 23, no. 4, pp. 313–322, 2016. View at Publisher · View at Google Scholar
  9. M. R. Haymart, M. Banerjee, D. Yang, A. K. Stewart, R. J. Koenig, and J. J. Griggs, “The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer,” Cancer, vol. 119, no. 2, pp. 259–265, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. B. R. Haugen, E. K. Alexander, K. C. Bible et al., “2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer,” Thyroid, vol. 26, no. 1, pp. 1–133, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. C. D. Smith, R. Grondin, W. Lemaster, B. Martin, B. T. Gold, and K. B. Ain, “Reversible cognitive, motor, and driving impairments in severe hypothyroidism,” Thyroid, vol. 25, no. 1, pp. 28–36, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. M. R. Haymart, M. Banerjee, D. Yang et al., “Variation in the management of thyroid cancer,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 5, pp. 2001–2008, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Van Den Bruel, J. Francart, C. Dubois et al., “Regional variation in thyroid cancer incidence in Belgium is associated with variation in thyroid imaging and thyroid disease management,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 10, pp. 4063–4071, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Trocchi, A. Kluttig, H. Dralle, C. Sekulla, M. Biermann, and A. Stang, “Thyroid cancer surgery in Germany: an analysis of the nationwide DRG statistics 2005-2006,” Langenbeck's Archives of Surgery, vol. 397, no. 3, pp. 421–428, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. S. P. Yang, L. S. Ying, S. Saw, R. M. Tuttle, K. Venkataraman, and C. Su-Ynn, “Practical barriers to implementation of thyroid cancer guidelines in the Asia-Pacific Region,” Endocrine Practice, vol. 21, pp. 1255–1268, 2015. View at Google Scholar